CEO Executive AssistantTime management for pharma health economics is not a topic that appears on most CEO leadership development curricula, but it shapes some of the most consequential decisions in a pharmaceutical company’s commercial lifecycle. Health economics and outcomes research, known as HEOR, determines how payers evaluate your products, what reimbursement frameworks apply to your therapies, and ultimately whether patients in major markets can access what you have developed.
A pharma CEO who is disengaged from HEOR strategy until a reimbursement rejection arrives is a CEO who has allowed a critical commercial risk to develop without adequate governance. A CEO who is too deep in health economics modeling is one who is substituting for their HEOR and market access teams rather than leading them. The challenge, as with most specialized functions in pharma leadership, is calibrating the right level of involvement and timing that investment well.
This guide addresses how to structure CEO time around HEOR strategy, payer value dossier reviews, and evidence generation investment decisions across the product lifecycle.
Health Economics and the CEO’s Strategic Stake
Before addressing how to manage time in this domain, it helps to be specific about why CEOs need to be involved at all. Health economics is a technical discipline with its own models, literature, and professional standards. Most CEOs are not health economists, and they should not pretend to be. But the outputs of health economics, particularly payer coverage decisions, have direct strategic consequences that only the CEO can fully address.
Payer decisions determine revenue. In major markets including the United Kingdom, Germany, France, Japan, and increasingly in the United States through value-based contracting, payer assessment of your product’s cost-effectiveness and clinical benefit directly shapes the price you can achieve and the patient population that can access your therapy. A product with strong clinical efficacy but weak health economics evidence may face restricted coverage, prior authorization burdens, or formulary placement that severely limits its commercial trajectory.
Investment decisions in evidence generation are long-cycle decisions with significant capital implications. Deciding whether to invest in a new outcomes registry, fund a comparative effectiveness study, or pursue a patient-reported outcomes instrument takes time and resources that must be weighed against other priorities. These decisions are made two to four years before the evidence they generate affects a payer dossier. The CEO who waits until launch to understand the evidence landscape is already years behind.
According to Harvard Business Review’s analysis of pharmaceutical value creation, companies that build market access and payer evidence strategies early in the development process, with senior leadership engagement, consistently outperform those that treat market access as a late-stage commercial function. CEO involvement in HEOR strategy is not a nicety. It is a value driver.
Mapping the HEOR Calendar to CEO Involvement
The HEOR lifecycle maps naturally onto the product development and commercial lifecycle. Understanding where your products sit in that lifecycle helps you identify when CEO engagement with health economics adds the most value.
Early development stage. At this stage, target product profile decisions are still being made and clinical trial designs are being finalized. This is when health economics input is most leverage-rich and when CEO involvement matters most for ensuring that HEOR strategy is integrated into development planning rather than bolted on afterward. The CEO’s role here is not to design the evidence strategy but to ask whether it exists, whether it is adequately resourced, and whether the clinical development team is incorporating payer requirements into trial endpoints and data collection. A single 60-minute strategy session with your Chief Medical Officer and Head of Market Access each year for each pipeline product in early development is a well-placed investment.
Late development and pre-submission stage. As a product approaches submission, health economics modeling is being developed in parallel with the clinical dossier. Payer advisory boards are being convened. Payer value dossiers are being drafted. This is where CEO involvement in dossier review becomes relevant. You should review the payer value dossier for each major market before submission, not to validate the technical modeling but to ensure that the strategic narrative is compelling and accurate, that the value story reflects what you know about the product from clinical development, and that the evidence gaps acknowledged in the dossier have a plan for resolution.
Post-launch and lifecycle management stage. After launch, real-world evidence generation becomes central. Your HEOR team is working to build the post-launch data package that supports coverage maintenance, label expansions, and lifecycle management. The CEO’s role here is primarily investment governance: reviewing the evidence generation portfolio annually, making resourcing decisions for new real-world data initiatives, and understanding how your evidence base compares to emerging competitor data.
Reviewing Payer Value Dossiers: A Framework for CEO Engagement
The payer value dossier is the primary document through which health technology assessment bodies and payer organizations evaluate the cost-effectiveness and comparative clinical benefit of your product. These are detailed, technically complex documents. A CEO who tries to review every element of a value dossier is investing time poorly. A CEO who signs off without meaningful engagement is abdicating a strategic responsibility.
The right CEO review of a payer value dossier focuses on four elements.
The clinical value narrative. How is your product’s clinical benefit characterized relative to standard of care? Is this characterization consistent with how your clinical team describes the product internally and with how the FDA-approved label reads? CEOs are often better positioned than market access staff to identify inconsistencies between the clinical narrative in a dossier and the organizational understanding of what the product actually does.
The comparator selection. Which comparators are used in the economic model, and does that selection reflect the true competitive landscape? In some cases, market access teams choose comparators strategically rather than reflectively. CEOs who understand the competitive landscape can identify when a comparator selection creates credibility risk.
The evidence gaps and their implications. Every dossier acknowledges evidence gaps. What are they, and what is the mitigation plan? Evidence gaps that are acknowledged without a clear real-world data strategy become payer leverage points. The CEO should know what the significant gaps are and confirm that the evidence generation plan addresses them.
The pricing and access ask. What is the market access team requesting in terms of coverage, pricing, and formulary position? Is this ask consistent with what you know about the payer environment in this market? Is it achievable given the evidence base you have?
A CEO dossier review, structured this way, takes approximately two hours per major market per product. For a company with multiple products and multiple major market submissions in a year, that is a significant but manageable time commitment. Schedule these reviews at least six weeks before dossier submission to ensure there is time to revise if needed.
Evidence Generation Investment Decisions
Investing in health economics evidence generation involves capital allocation decisions that are among the most complex in the pharma portfolio: they are long-cycle, their payoff is uncertain, and the connection between the investment and the downstream commercial outcome is often difficult to trace directly.
The CEO’s role in evidence generation investment is governance, not design. Your HEOR leadership and Market Access team should be the ones proposing and managing the evidence generation portfolio. Your role is to ensure that the portfolio is strategically coherent, adequately resourced, and reviewed at appropriate intervals.
Build an annual evidence generation portfolio review into your calendar. This review, typically 90 minutes to two hours, should cover the current real-world evidence studies in progress, proposed new initiatives and their rationale, the evidence landscape for your major competitors, and the resource requirements for the proposed portfolio. The output should be a prioritized portfolio with clear ownership and milestones.
Between annual reviews, evidence generation decisions that meet specific thresholds should be escalated for CEO input. These thresholds include studies requiring more than a defined budget (you should specify what that threshold is for your organization), studies that involve novel methodologies with significant strategic risk, studies that require partnership with competitor companies (which carries both strategic and antitrust considerations), and studies whose findings will affect pending regulatory or reimbursement submissions.
Studies below these thresholds should be managed within the HEOR and Market Access organization without CEO escalation.
Structuring the HEOR Leadership Relationship
The CEO’s engagement with health economics strategy is mediated primarily through the Head of Market Access and, in some organizations, a Chief Commercial Officer or Head of HEOR who sits at the executive level. The quality of this relationship directly shapes the quality of CEO oversight in this domain.
Invest in a standing one-on-one with your Head of Market Access, at least monthly. Use these meetings not only for status updates but for strategic thinking: what payer trends are emerging that will affect your portfolio? What evidence gaps are you most concerned about? Are there competitive dynamics in reimbursement that you should understand?
This relationship also serves as an early warning system. Payer decisions rarely arrive without signals. HTA bodies publish guidance documents, issue advisory opinions, and engage with manufacturers during assessment processes. A Market Access leader who is keeping you informed of these signals as they emerge, rather than after they crystallize into decisions, gives you the ability to respond strategically rather than reactively.
Delegation frameworks for pharma executives offer a model for building this kind of proactive advisory relationship with senior functional leaders, including how to set the right information-sharing expectations without micromanaging operational decisions.
Common CEO Time Management Mistakes in HEOR
The two most common errors pharma CEOs make in health economics are mirror images of each other.
The first is disengagement until a crisis. This is the CEO who considers HEOR a specialized function, trusts it to their market access team, and only surfaces when a major market access rejection creates a commercial crisis. By the time the rejection arrives, the options for response are significantly narrowed. The evidence base that would have supported a different outcome needed to be built years earlier. The CEO who is not involved in HEOR strategy during development is not avoiding work. They are deferring work with interest.
The second error is the CEO who becomes too involved in the technical details of economic modeling. Health economics models involve complex assumptions about disease progression, treatment patterns, resource utilization, and comparative effectiveness. The CEO who spends time interrogating model structure and parameter assumptions is doing work that belongs to the HEOR team and their methodological advisors. This kind of over-involvement signals distrust, creates confusion about decision authority, and consumes CEO time that should be invested at a higher level of abstraction.
The right posture is engaged but strategic: informed about the evidence landscape, visible at key HEOR decision points, and genuinely curious about how payer thinking is evolving, without being a technical participant in the modeling process.
Connecting HEOR to Board Governance
Pharmaceutical boards are increasingly aware of market access risk as a strategic issue, particularly in the current environment of payer scrutiny, IRA implications in the US market, and evolving HTA methodology in Europe. CEOs who are engaged with their HEOR strategy are better positioned to communicate market access risk and opportunity to their boards in a credible, specific way.
Build health economics performance into your board reporting cadence. This does not require a detailed HEOR briefing at every board meeting. It does require that major market access decisions, reimbursement outcomes, and significant evidence generation investments are reported to the board with appropriate context. When a major market access rejection occurs, the board should hear from you, not through external channels first.
Time management for pharma CEOs addresses how to integrate specialized functional governance, including HEOR, into a broader CEO time structure that keeps strategic priorities protected.
Conclusion
Time management for pharma health economics is about matching CEO attention to the moments where strategic value is highest: early in the development lifecycle when evidence strategy is being set, at key dossier review milestones, and during annual evidence generation portfolio reviews. It is not about personal involvement in technical modeling or day-to-day market access operations.
The CEO who invests 10 to 15 hours annually in structured HEOR governance, positioned at the right points in the product and payer calendar, is a CEO who reduces market access risk, makes better evidence generation investment decisions, and leads a Market Access organization that understands its work as a strategic priority rather than a regulatory formality.
In markets where payer decisions increasingly determine commercial success, that investment is not optional. It is one of the highest-leverage uses of CEO time in the pharmaceutical development and commercial cycle.